PRA7
REGISTERED - SEC. 7 REQUEST ABANDONED
06/29/2026
Back to search
Official data from USPTO
CSL SEQIRUS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CSL SEQIRUS
ST13
US500000097542504Class
1, 5, 41, 42, 44
Filing
97542504
Registration
7877427
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
06/29/2026
Trademark type
Word
Nice classes
1, 5, 41, 42, 44
Filing date
08/10/2022
Registration date
08/05/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/05/2025
Last transaction
06/29/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Maidenhead, Berkshire, GB
Examiner
CAYSIDO, REBECCA TOLENTINO
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Seqirus UK Limited
Representatives
Nancy Sabarra FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical and biological reagents for scientific purposesresearch purposesnon-medical purposes; cell culture reagents and media for scientific and research use; laboratory and scientific test kits for laboratory or research usereagent kits comprising generic DNA circleDNA primerspolymerase and buffers for use in biotechnology fields; chemical preparations for scientific and industrial purposes; diagnostic and testing agentsdiagnostic reagents and diagnostic testing preparations for scientific and research use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for antibody screeningblood groupingfor the typing and detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes all for non-medical purposes; chemical test kits for the detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screeningblood groupingthe typing and detection of specific blood cells
Class 5
Pharmaceutical preparations and substances for the treatment and prevention of influenzarespiratory disease and disordersinfectious diseases and disorderscardiovascular diseases and disordersstrokeheart failure; pharmaceutical preparations and substancesanti-virals and antibiotics; vaccines; blood productsblood for medical purposesblood plasma and cord blood for medical purposes; serumsanti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; antibodies for use in the treatment of infectious diseasescancer and autoimmune diseases; monoclonal and polyclonal antibodies for medical purposes; therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; influenza vaccines; adjuvants for medical purposes and antigens being protein arrays for medical purposes; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disorders; blood productsblood plasmareagent blood cells for medical use; products derived from blood and products derived from recombinant DNA technologyblood substitutes being immunoglobulinshuman albuminblood clotting factorsplasma volume expandersblood proteins for therapeutic human use; test kitsinvitro diagnostic reagent test kits comprised of medical diagnostic reagents for use in detecting cell mediated immune response; pharmaceutical preparations and substancesRhD reagents for medical use for the detection of specific antigens and in blood typing; pharmaceutical preparationsreagent red blood cells for medical purposes used to detect antibodies or IgG subtypes; pharmaceutical preparationsmonoclonal and polyclonal antibodies for pharmaceutical use; pharmaceutical preparationsreagents for medical and clinical use for the typing and detection of specific blood cellsthe detection of relevant compliment components and immunoglobulin subtypes; diagnostic agents for medical purposes
Class 41
Education services including medical education servicesconducting classesseminarsconferencesworkshops in the fields of pharmaceuticalsvaccinesbiotechnologybiotherapyimmunologyrare diseases and blood conditions; health educationproviding classes in the field of healthvaccinesimmunology; consultancy services relating to education; provision of education servicesarranging and conducting of online conferences and symposia in the field of medical science via an online forum; provision of medical training and education courses in the field of health and medicine; publication of electronic educational materials; dissemination of printed and electronic educational material of others in the field of health and medicine; weblog servicesproviding online non-downloadable blogs in the field of health and medicine; electronic publication of information on a wide range of topicsincluding online and over a global computer networkelectronic publishing of electronic publications featuring information on a wide range of topics
Class 42
Scientific and technological servicesscientific research and product development in the field of vaccines; scientific researchanalysistesting in the field of medicinepharmaceuticalsvaccinesbiotechnology; research and development servicesscientificmedicalpharmaceutical and blood products research and development services; industrial analysis of biotechnology and immunology processes for product development in the field of pharmaceuticals and vaccines; providing medical research and scientific research information about the results of clinical trials for pharmaceuticals and vaccines; providing medical research and scientific research information in the field of clinical trials; provision of testing facilities for pharmaceutical research; laboratory analysis and research in the fields of pharmaceuticalsvaccinesbacteriologychemistry; management of scientific research projects; providing technical research in the field of pharmaceutical studies through preparation of technical studiestechnical reportsscientific reports; providing technical research in the field of pharmaceutical studies through preparation of scientific and medical research projectspreparation of statistics and reports relating to scientific and medical research; provision of scientific research services and facilitiesprovision of scientific research resultsinformation and outcomes in the field of health and medicine; provision of pharmaceutical research information relating to the aforementioned services; pharmaceutical research advisory and consultancy services relating to the aforementioned services; dissemination of pharmaceutical research and medical research information relating to the aforementioned services over a global computer network; medical laboratory services through scientific testing and screening servicesmedical laboratory testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma
Class 44
Medical services; medical information services; health care services; health care information services; patient support servicesproviding an internet-based database of patient medical information where patients can inquire about medical issues and procedures related to vaccination and immunology; providing medical information concerning blood products; providing medical information concerning vaccinesanti-venoms and immunohaematology products being diagnostic reagents; patient support servicesproviding patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database
Publications
History of USPTO decisions and trademark events.
45 publications found
PRAN
POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED
06/29/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/20/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/17/2025
ES7R
TEAS SECTION 7 REQUEST RECEIVED
08/27/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/05/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
08/05/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/17/2025
PUBO
PUBLISHED FOR OPPOSITION
06/17/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/11/2025
ATRV
ATTORNEY REVIEW COMPLETED
05/29/2025
OTHE
CASE RETURNED TO EXAMINATION
05/27/2025
IUCN
NOTICE OF ALLOWANCE CANCELLED
05/27/2025
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
05/23/2025
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
05/23/2025
APET
ASSIGNED TO PETITION STAFF
05/19/2025
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
04/16/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/25/2025
EX2G
SOU EXTENSION 2 GRANTED
03/24/2025
EXT2
SOU EXTENSION 2 FILED
03/24/2025
EEXT
SOU TEAS EXTENSION RECEIVED
03/24/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/19/2024
EX1G
SOU EXTENSION 1 GRANTED
09/19/2024
EXT1
SOU EXTENSION 1 FILED
09/19/2024
EEXT
SOU TEAS EXTENSION RECEIVED
09/19/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/26/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/30/2024
PUBO
PUBLISHED FOR OPPOSITION
01/30/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/10/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/28/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
12/28/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/28/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
12/28/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/28/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/06/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/05/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
08/15/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
08/15/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/05/2023
GNRT
NON-FINAL ACTION E-MAILED
06/05/2023
CNRT
NON-FINAL ACTION WRITTEN
06/05/2023
DOCK
ASSIGNED TO EXAMINER
05/30/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/30/2022
NWAP
NEW APPLICATION ENTERED
08/13/2022
Continuous trademark protection
Get notified about every new filing that threatens CSL SEQIRUS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.